Meinian Health H1 2026 Revenue Down 6.45%, AI-Related Income Up 55.96%

Meinian Health disclosed its 2026 semi-annual report on the evening of August 30. During the reporting period, the company achieved operating revenue of RMB 3.844 billion, a year-on-year decrease of 6.45%. Net profit attributable to shareholders of the listed company was RMB -182 million, narrowing the loss compared with the same period last year. Basic earnings per share were RMB -0.05. As of June 30, 2026, Meinian Health operated a total of 546 examination centers, of which 295 were controlled centers. In the first half of the year, the average check-up price was RMB 628, and total visits reached 9.25 million, with controlled centers receiving 5.75 million visits.

During the reporting period, revenue derived from AI-integrated technologies in the company's main business amounted to RMB 219 million, an increase of 55.96% compared with the same period in 2025. This mainly included revenue from projects such as cardiopulmonary combined screening, AI bone density, capsule gastroscopy, AI-MDT reports, Feijiening, and Naoruijia. In its semi-annual report, Meinian Health stated that the performance change was mainly due to the industry's strong seasonality, with the first half being the traditional off-season. Affected by holiday distribution and the financial accounting cycles of enterprises and public institutions, some corporate budgets and check-up schedules were deferred. Overall order signing remained relatively stable, and business affected by the pace of check-up visits is expected to be gradually released in the second half of the year. The company will actively promote business growth among government, corporate, banking, and insurance clients, and continue to increase the proportion of national client contracts and check-up share. In the first half, efficiency improvement and cost reduction progressed steadily, with the company continuing to leverage AI and digitalization to drive efficiency, cost reduction, and innovative revenue generation.

Regarding shareholders, Meinian Health's 2026 first-quarter report showed that Fang Wenyan and Zhang Jianping newly entered the top ten shareholders, holding 127 million shares and 66.2574 million shares, respectively, ranking as the third and tenth largest shareholders. The latest semi-annual report shows that both Fang Wenyan and Zhang Jianping have exited the top ten shareholders of Meinian Health. The newly entered tenth largest shareholder is the E Fund Management Co. , Ltd. - Social Security Fund 17042 Portfolio, holding approximately 48.7 million shares.

The 2026 semi-annual reports of listed companies show that Zhang Jianping exited the top ten shareholders of Western Materials, China Northern Rare Earth, and Dongcai Technology, while Fang Wenyan and Zhang Jianping simultaneously exited the top ten shareholders of Sichuan Gold. Zhang Jianping newly became the seventh largest shareholder of Kexiang Co. , the fourth largest shareholder of Yunnan Germanium, the ninth largest shareholder of Zhongji Innolight, and the third largest shareholder of Hangzhou Cable. Zhang Jianping and Fang Wenyan simultaneously became the fifth and eighth largest shareholders of Hengtong Optic-Electric.